Patents by Inventor Barbara Czako

Barbara Czako has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLS1 inhibitors for treating disease
    Patent number: 11958849
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: April 16, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • PTPN11 inhibitors
    Patent number: 11945815
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: April 2, 2024
    Inventors: Philip Jones, Barbara Czako, Christopher L Carroll, Pijus Mandal, Jason Cross
  • INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE
    Publication number: 20240043384
    Abstract: Disclosed herein are compounds which inhibit PU.1, pharmaceutical formulations, and methods of treatment of PU.1-mediated diseases, such as Alzheimer's disease, inflammation, and diseases related to excessive myelin uptake.
    Type: Application
    Filed: October 5, 2023
    Publication date: February 8, 2024
    Inventors: Barbara CZAKO, William RALVENIUS, Li-Huei TSAI
  • Heterocyclic inhibitors of PTPN11
    Patent number: 11840536
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: December 12, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Philip Jones, Barbara Czako, Jason Cross, Paul Leonard, Faika Mseeh, Connor Parker
  • UREA INHIBITORS OF MICRO-RNA
    Publication number: 20230145868
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of the expression of miRNA, for use in the treatment or prevention of cancer.
    Type: Application
    Filed: December 22, 2022
    Publication date: May 11, 2023
    Inventors: George CALIN, Philip JONES, Barbara CZAKO, Simone ANFOSSI
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20230124815
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 25, 2022
    Publication date: April 20, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • HETEROCYCLIC INHIBITORS OF PTPN11
    Publication number: 20230109858
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: July 29, 2022
    Publication date: April 13, 2023
    Inventors: Philip JONES, Barbara CZAKO, Jason CROSS, Paul LEONARD, Faika MSEEH, Connor PARKER
  • Heterocyclic inhibitors of PTPN11
    Patent number: 11466017
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: October 11, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Philip Jones, Barbara Czako, Jason Cross, Paul Leonard, Faika Mseeh, Connor Parker
  • GLS1 inhibitors for treating disease
    Patent number: 11370786
    Abstract: Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: June 28, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • PTPN11 INHIBITORS
    Publication number: 20220041594
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 10, 2022
    Inventors: Philip JONES, Barbara CZAKO, Christopher L. CARROLL, Pijus MANDAL, Jason CROSS
  • PTPN11 inhibitors
    Patent number: 11104675
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 31, 2021
    Assignee: NAVIRE PHARMA, INC.
    Inventors: Philip Jones, Barbara Czako, Christopher L. Carroll, Pijus Mandal, Jason Cross
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 11001594
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 11, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • HETEROCYCLIC INHIBITORS OF PTPN11
    Publication number: 20210017182
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: August 10, 2020
    Publication date: January 21, 2021
    Inventors: Philip JONES, Barbara CZAKO, Jason CROSS, Paul LEONARD, Faika MSEEH, Connor PARKER
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20200407353
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 10, 2020
    Publication date: December 31, 2020
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Heterocyclic inhibitors of PTPN11
    Patent number: 10851110
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: December 1, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Philip Jones, Barbara Czako, Jason Cross, Paul Leonard, Faika Mseeh, Connor Austin Parker
  • GLS1 inhibitors for treating disease
    Patent number: 10766892
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • PTPN11 INHIBITORS
    Publication number: 20200048249
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: August 9, 2019
    Publication date: February 13, 2020
    Inventors: Philip JONES, Barbara CZAKO, Christopher L. CARROLL, Pijus MANDAL, Jason CROSS
  • HETEROCYCLIC INHIBITORS OF PTPN11
    Publication number: 20190270746
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: February 7, 2019
    Publication date: September 5, 2019
    Inventors: Philip JONES, Barbara CZAKO, Jason CROSS, Paul LEONARD, Faika MSEEH, Connor Austin PARKER
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20190270736
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20190270753
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 5, 2019
    Inventors: Philip JONES, Maria Emilia DI FRANCESCO, Alessia PETROCCHI, Christopher L. CARROLL, Joe MARSZALEK, Barbara CZAKO, Ryan JOHNSON, Jay THEROFF